Stockscreener 앱 받기
0.735
2.65%
-0.02
시간 외 거래:
.74
0.005
+0.68%
Adicet Bio Inc 주식(ACET)의 최신 뉴스
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference - BioSpace
Adicet Bio Strengthens Team with Strategic Stock Options Package for Key New Hires - Stock Titan
Adicet Bio Reveals Next-Gen CAR-T Strategy for Autoimmune Diseases at Major Conference - Stock Titan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Consensus Target Price from Brokerages - Defense World
The Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi and ACET ($ACT) Drive Blockchain Payment Innovation in UAE’s $3.9 Billion USD Initiative - GlobeNewswire Inc.
Adicet Bio (NASDAQ:ACET) Earns “Buy” Rating from Guggenheim - The AM Reporter
Adicet Bio (ACET): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
Guggenheim Reiterates Buy Rating for Adicet Bio (NASDAQ:ACET) - Defense World
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
Short Interest in Adicet Bio, Inc. (NASDAQ:ACET) Drops By 16.9% - Defense World
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com Canada
Adicet Bio’s SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Adicet Bio (ACET) Expected to Announce Earnings on Tuesday - Defense World
Promising Pipeline and Strong Financials Drive Buy Rating for Adicet Bio - TipRanks
Adicet Bio (NASDAQ:ACET) Earns “Neutral” Rating from HC Wainwright - Defense World
Adicet Bio Advances Clinical Trials and Financial Stability - TipRanks
H.C. Wainwright maintains Neutral on Adicet Bio stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Neutral on Adicet Bio stock - Investing.com India
Cautious Hold Rating on Adicet Bio Amid Early-Stage Clinical Developments and Uncertain Outcomes - TipRanks
Adicet Bio: Hold Rating Amid Fair Valuation and Awaited Clinical Data - TipRanks
Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million -March 06, 2025 at 04:59 pm EST - Marketscreener.com
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Lelezard
Adicet Bio, Inc Q4 Loss Decreases - Nasdaq
Adicet Bio reports Q4 EPS (32c), consensus (35c) - TipRanks
Can Adicet Bio's $176M War Chest and Fast Track Status Transform Autoimmune Treatment? - StockTitan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $7.50 Average Target Price from Analysts - Defense World
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update - Defense World
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - BioSpace
Adicet Bio's (ACET) "Neutral" Rating Reaffirmed at HC Wainwright - MarketBeat
Adicet Bio shares rise on FDA Fast Track Designation for ADI-001 - Investing.com
FDA fast tracks Adicet Bio's autoimmune therapy By Investing.com - Investing.com South Africa
FDA fast tracks Adicet Bio’s autoimmune therapy - Investing.com
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Lelezard
FDA fast tracks Adicet Bio’s autoimmune therapy By Investing.com - Investing.com UK
Adicet's Systemic Sclerosis Therapy Earns Critical FDA Fast Track StatusWhat This Means for Patients - StockTitan
Adicet Bio (NASDAQ:ACET) versus Corvus Pharmaceuticals (NASDAQ:CRVS) Head to Head Analysis - Defense World
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year By Investing.com - Investing.com South Africa
Adicet Bio's SWOT analysis: gamma-delta T cell stock faces pivotal year - Investing.com
Healthy Upside Potential: Adicet Bio Inc (ACET) - SETE News
Adicet Bio Inc [ACET] Insider Activity: An Update for Investors - Knox Daily
Investor Alert: What’s Really Going On At Adicet Bio Inc (NASDAQ: ACET) - Stocks Register
Adicet Bio (NASDAQ:ACET) Earns Market Perform Rating from JMP Securities - MarketBeat
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.50 - MarketBeat
Adicet Bio reports progress in clinical trial enrollments - MSN
HC Wainwright Reaffirms Neutral Rating for Adicet Bio (NASDAQ:ACET) - MarketBeat
Adicet Bio (NASDAQ:ACET) Earns “Market Perform” Rating from JMP Securities - Defense World
3.89%
0.13%
자본화:
|
볼륨(24시간):